Yet, despite these gaps in understanding, the finding that RB is important for HR repair reveals a potential vulnerability: Tumors lacking RB might be exploited therapeutically by treatments similar to those used for other cancers with impaired HR repair (e.g., PARP inhibitors) [95,98,114]. Here, RB1 is linked to cancer.